This text provides general information and is no substitute for medical advice. Diagnosis and treatment belong in the hands of neurologists; never stop prescribed medication on your own. Rules, approvals and guidelines differ from country to country; sources marked (German) refer to Germany.
Why this comparison?
For many approaches we have detailed pages. Here they stand side by side for the first time: what they were studied for, how solid the evidence is, what applies legally in Germany, and where the risks and limits lie.
The table summarises what we know from the sources named. Where we lack a verified source, it says so explicitly. You never change or stop a prescribed therapy on your own, only after talking to your neurologist. Legal information refers to Germany; rules differ from country to country.
The comparison in one table
| Approach | Studied for | Level of evidence | Evidence and source | Legal status in Germany | Main risks and limits | Learn more |
|---|---|---|---|---|---|---|
| Disease-modifying therapies (conventional) | Fewer relapses and new MRI lesions, delaying progression. | established | These drugs reduce the number of relapses and new MRI lesions and can delay progression; the guideline groups them by disease activity. Source: DGN/AWMF guideline 030-050 (German). | Approved medicines, prescribed by a doctor. | Each substance has its own side effects and monitoring. For primary progressive MS there are fewer approved options. Never stop on your own. | MS treatments at a glance |
| Relapse treatment and symptom treatment | Relapses with noticeable impairment; spasticity, bladder problems, pain, fatigue, depression. | established | For a relapse usually high-dose cortisone over a few days, if needed blood-cleansing procedures; complaints are treated with medication, physiotherapy, occupational therapy, speech therapy, neuropsychology and rehabilitation. Source: DGN/AWMF guideline 030-050 (German). | Treatment prescribed by a doctor. | Which measure fits depends on the symptom and the person and is decided with your doctor. | MS treatments at a glance |
| Cannabis-based medicines (spasticity, pain) | Spasticity, neuropathic pain, bladder complaints. | establishedfor spasticity only, effect mostly patient-reported; pain and bladder: preliminary; disease course: not established | Meta-analyses show less patient-reported spasticity, objective measures often show smaller effects; for pain and bladder the data are weaker, and oral THC had no significant effect on progression in the CUPID trial. Sources: meta-analysis (PubMed Central), CAMS-LUTS, CUPID. | Only on a doctor's prescription; health insurance does not cover the cost automatically. | Dizziness, tiredness, dry mouth; poorer results in thinking tests with regular use; psychotic reactions are possible and dose-dependent; interactions with MS drugs (e.g. cladribine, S1P modulators); fitness to drive must be considered. | Cannabis and MS |
| Psilocybin | Research in depression and anxiety; in MS itself so far only hints of neuroplasticity and anti-inflammatory effects. | preclinical onlyfor MS; controlled studies exist for depression | The phase 3 trial COMP005 met its primary endpoint in treatment-resistant depression; for MS there are only preclinical hints; a phase 2 trial (PsyPal) on psychological distress in life-limiting illness, including MS, is ongoing. Sources: Compass Pathways, ClinicalTrials.gov NCT06782724. | Subject to the German Narcotics Act (BtMG) and not approved for medical use in Germany; studies run under controlled conditions. | Headache, nausea, temporary anxiety. Not suitable in, among others, psychotic illness, a family history of psychosis, epilepsy, uncontrolled high blood pressure. Long-term safety in MS is unclear. | Psilocybin and MS |
| Medicinal mushrooms (e.g. lion’s mane) | Nerve protection and myelin formation in laboratory and animal models. | preclinical only | Preclinical studies show promotion of the maturation of myelin-forming cells; in humans there is a pilot study in healthy volunteers, but no study in MS. For reishi and a few other species there are also only animal studies; for the remaining entries of the database a PubMed search of 18 Nov 2026 found no MS study. Sources: Hericium erinaceus studies (PubMed Central), PMID 36004706, 41957858. | Sold as food supplements, not an approved MS medicine. | Mushroom allergy; possible effect on blood clotting (caution with blood thinners); possible influence on MS drugs; products are not uniformly standardised; not sufficiently studied in pregnancy and breastfeeding. | Medicinal mushrooms |
| Medicinal plants | The database lists goals such as stress, fatigue or inflammation for each plant. | not establishedpreliminary hints for individual plants | A PubMed search of 18 Nov 2026 across all entries of the database found no plant with a guideline recommendation or several studies with a clearly positive result in MS. Small controlled studies with preliminary hints exist for individual plants (e.g. lavender and saffron for fatigue, ginger for gastrointestinal complaints), and studies without benefit for ginkgo and green tea extract. Sources: PMID 35803088, 32716906, 37891539, 22955125, 33762428; details under Medicinal plants. | Sold as food supplements, not an approved MS medicine. | Interactions with medication are possible, especially with immunotherapy; clarify with your doctor before use. | Medicinal plants |
| Diet | Inflammation, fatigue, quality of life, body weight and accompanying conditions. | preliminary | No diet reliably affects relapses or MRI activity, except indirectly through body weight; a balanced, plant-based diet is recommended and showed benefits for inflammation markers, fatigue and quality of life. Sources: DGN/AWMF guideline 030-050 (German), WAVES trial. | Not a medicine, no prescription needed. | There is no MS cure-all diet. Restrictive diets can lead to nutrient deficiencies (B12, iron, calcium), bone loss and underweight. No diet replaces disease-modifying therapy. | Podcast on diet (German) |
| Exercise and physiotherapy | Fatigue, balance, walking, spasticity, mood and quality of life. | establishedas part of symptomatic therapy | According to the guideline, physiotherapy, occupational therapy and rehabilitation are part of symptomatic MS treatment. Source: DGN/AWMF guideline 030-050 (German). | Physiotherapy and occupational therapy on a doctor's prescription; everyday exercise is freely available. | Type and intensity must fit the person and are agreed with neurology and therapists; practices such as tai chi need good instruction. | Podcast on exercise (German) |
The levels of the evidence traffic light are explained below under “How we rate evidence”. On small screens each approach appears as its own block.
The approaches in detail
Disease-modifying therapies
They are the foundation of treatment. The drugs reduce the number of relapses and new MRI lesions and can delay progression. The guideline distinguishes substances for milder and for active courses; the choice depends on disease activity, disease course, other conditions and plans for a family, among other things. New substances such as BTK inhibitors are being studied. More under MS treatments at a glance.
Relapse treatment and symptom treatment
For a relapse with noticeable impairment, high-dose cortisone is usually given; if that is not enough, blood-cleansing procedures may be considered. Spasticity, bladder problems, pain, fatigue or depression can be treated independently of the disease course, with medication and with physiotherapy, occupational therapy, speech therapy, neuropsychology and rehabilitation. Both are part of standard care guided by doctors.
Cannabis-based medicines
Cannabis is best studied for MS-related spasticity: meta-analyses show less patient-reported spasticity, while objective measures often show smaller effects. For pain and bladder complaints the data are weaker. In the CUPID trial, oral THC had no significant effect on the progression of MS. There are side effects and possible interactions with MS drugs, so treatment belongs in medical hands. Details and legal status: Cannabis and MS.
Psilocybin
Psilocybin is mainly researched in depression and anxiety. For MS there are so far only preclinical hints of neuroplasticity and anti-inflammatory effects; an ongoing phase 2 trial (PsyPal) studies psychological distress in life-limiting illness, MS included. In Germany psilocybin is subject to the Narcotics Act and is not approved for medical use. We give no information on obtaining or using it. The state of research is on Psilocybin and MS.
Medicinal mushrooms
For lion’s mane, preclinical studies show effects on nerve protection and the maturation of myelin-forming cells. A study in people with MS is missing; the existing pilot study involved healthy volunteers. For reishi and a few other species there are also only animal studies (PMID 36004706, 41957858); for the remaining mushrooms of the database a PubMed search of 18 Nov 2026 found no MS study. Medicinal mushrooms are food supplements; because of possible interactions, talk to your neurologist first. More under Medicinal mushrooms.
Medicinal plants
The Medicinal plants page lists plant substances with active compounds and stated goals. A PubMed search of 18 Nov 2026 found no guideline recommendation or several studies with a clearly positive result in MS for any of the 61 plants, which is why the traffic light says “not established”. For individual plants there are small controlled studies with preliminary hints (e.g. lavender and saffron for fatigue, ginger for gastrointestinal complaints); for most plants there are only animal studies or no MS studies. That does not mean a plant is ineffective, only that the evidence is missing. The rating per plant is in the column “Evidence in MS” on the Medicinal plants page. Interactions with MS drugs are possible.
Diet
No diet cures MS or reliably prevents relapses. A balanced, mainly plant-based diet is recommended; being overweight is considered unfavourable for the course of the disease. Vitamin D deficiency is common in MS; have your level checked by a doctor and never take high doses without a blood test. Restrictive diets carry the risk of nutrient deficiencies. For a start, see our podcast on diet and supplements (in German).
Exercise and physiotherapy
Physiotherapy, occupational therapy and rehabilitation are an established part of symptomatic therapy. How much and which exercise suits you depends on your symptoms and how you feel that day, and is agreed with neurology and therapists. We discuss the current evidence on sport in our podcast on exercise in MS (in German).
How we rate evidence
Not every study says the same amount. We rank statements by who was studied: first in the cell, then in the animal, then in humans, finally in large controlled trials and guidelines. The further along, the more reliable the statement is for people with MS.
- Established: effectiveness described in controlled studies in humans or in the guideline for a specific area of use. The rating applies only to that area of use.
- Preliminary: there are studies in humans, but they are small, inconsistent or not directly about MS. The results still have to be confirmed.
- Preclinical only: findings come from cell culture or animal models. They show possible mechanisms but do not say whether something helps people with MS.
- Not established: we have no verified human study source in MS, or the studies showed no effect.
The traffic light says nothing about whether an approach is safe for you personally. You clarify that with your neurologist.
Frequently asked questions
Can I replace my MS therapy with cannabis, psilocybin or medicinal mushrooms?
No. According to the sources named here, none of the complementary approaches replaces a disease-modifying therapy. Always discuss changes to your therapy with your neurologist first.
What does “preclinical only” mean?
The findings come from cell cultures or animal experiments. They do not show that the same effect occurs in people with MS.
Is psilocybin allowed for MS?
In Germany psilocybin is subject to the Narcotics Act and is not approved for medical use. Research takes place in studies under controlled conditions. We give no information on obtaining or using it.
Sources
- DGN/AWMF guideline (German): diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-IgG-associated diseases (030-050)
- Deutsche Multiple Sklerose Gesellschaft (DMSG), federal association (German)
- Cannabinoids for spasticity in patients with multiple sclerosis: a systematic review and meta-analysis. PubMed Central
- The effect of cannabinoids on lower urinary tract symptoms in multiple sclerosis: a randomised placebo controlled trial (CAMS-LUTS)
- The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial. NCBI
- Feinstein A et al.: Effects of cannabis on cognition in patients with MS: a psychometric and MRI study (2011)
- Drug-Cannabinoid Interactions in Selected Therapeutics for Symptoms Associated with Epilepsy, Autism Spectrum Disorder, Cancer, Multiple Sclerosis, and Pain. MDPI
- Compass Pathways: Phase 3 trial COMP005 of COMP360 psilocybin in treatment-resistant depression (2025)
- ClinicalTrials.gov NCT06782724: Psilocybin Therapy for Psychological Distress in Palliative Patients (PsyPal)
- Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein. PubMed Central
- Neurotrophic and Neuroprotective Effects of Hericium erinaceus. PubMed Central
- WAVES trial on diet, fatigue and quality of life in MS (PubMed 34377527)
As of: 2026-11-18. More basics: What is multiple sclerosis (MS)? · MS symptoms: early signs and typical complaints · MS diagnosis: how multiple sclerosis is established · MS treatments at a glance.